QLETLI
Phase 3Small molecule
QLETLI is one of 25 small molecule programs targeting Uveitis. It is currently in Phase 3.
1
Indications
1
Total Trials
1
Active Trials
24
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
26 competitors in Uveitis
#DrugCompanyPhaseTrials
1Humira
NovartisApproved
Trexall
Jazz PharmaceuticalsApproved
Thalomid
Bristol-Myers SquibbApproved
Taltz
Eli LillyApproved
Gilenya
NovartisApproved
Neoral
NovartisApproved
Decadron
AAspen Global Incorporated
Approved
Lupkynis
Aurinia PharmaceuticalsApproved
Olumiant
Eli LillyPhase 3
Ilevro
HHarrow Inc
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for QLETLI. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- BBio-Thera Solutions